Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.

Abstract

AIMS This study examined the effects of the CYP3A/P-glycoprotein inducer, rifampicin, on the pharmacokinetics of dabigatran following oral administration of the prodrug, dabigatran etexilate. METHODS This was an open-label, fixed-sequence, four-period study in healthy volunteers. Subjects received a single dose of dabigatran etexilate 150 mg on day 1… (More)
DOI: 10.1111/j.1365-2125.2012.04218.x

Topics

7 Figures and Tables